Last edition
News about "Interius BioTherapeutics"
Gilead's Kite Acquires Interius BioTherapeutics for USD 350 Million to Fuel In Vivo CAR-T Innovation
Gilead Sciences’ subsidiary Kite Pharma has announced the acquisition of Interius BioTherapeutics, a privately held biotech company, for USD 350 million in cash. The deal is aimed at advancing Kite’s development of in vivo CAR-T cell therapies, considered a next-generation approach to cancer treatment.
Interius BioTherapeutics | 22/08/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members